Breast cancer VPAC1 receptors

Terry W Moody; Robert T Jensen

doi:10.1196/annals.1317.058

Breast cancer VPAC1 receptors

Ann N Y Acad Sci. 2006 Jul:1070:436-9. doi: 10.1196/annals.1317.058.

Authors

Terry W Moody¹, Robert T Jensen

Affiliation

¹ Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. moodyt@mail.nih.gov

PMID: 16888206
DOI: 10.1196/annals.1317.058

Abstract

VIP receptors were investigated in breast cancer biopsy specimens. Twenty biopsy specimens bound 125I-VIP with high affinity. Also, each of the 20 biopsy specimens had high amounts of VPAC1 receptor mRNA. MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity. VIP chemotherapeutic conjugates may be useful agents to inhibit the growth of breast cancer.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Biopsy
Breast Neoplasms / classification
Breast Neoplasms / genetics
Breast Neoplasms / metabolism*
Cell Line, Tumor
Humans
Receptors, Vasoactive Intestinal Polypeptide, Type I / genetics
Receptors, Vasoactive Intestinal Polypeptide, Type I / metabolism*

Substances

Receptors, Vasoactive Intestinal Polypeptide, Type I

Grants and funding

Intramural NIH HHS/United States